Retatrutide - Top-Line Results from TRIUMPH 4

In this quick update, I break down the newest Phase 3 data for retatrutide, Lilly’s investigational triple-agonist medication showing unprecedented results in obesity and knee osteoarthritis.

Highlights:

• Up to 28.7% weight loss (~71 lbs) over 68 weeks
• 75% reduction in knee pain and major improvements in physical function
• Cardiometabolic benefits: lower triglycerides, non-HDL cholesterol, hsCRP, and blood pressure

We also cover

• Common side effects and safety signals
• Perceived excessive weight loss — and what this means for clinical practice in a new era of powerful medications
• A reality check on Canadian availability (likely 3+ years away)
• A strong warning about illegal online sales and the risks of buying unregulated products

A concise medical breakdown to help you stay informed and safe as the obesity-medicine landscape evolves.